Novartis (NVS) Stock Forecast & Price Target

$130.05 -1.01 (-0.77%)

Closing price 10/10/2025 03:59 PM Eastern

Extended Trading

$129.34 -0.71 (-0.55%)

As of 10/10/2025 07:52 PM Eastern

Compare

Novartis - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Hold

Based on 10 Analyst Ratings

Sell
3

Hold
4

Buy
3

Based on 10 Wall Street analysts who have issued ratings for Novartis in the last 12 months, the stock has a consensus rating of "Hold." Out of the 10 analysts, 3 have given a sell rating, 4 have given a hold rating, 2 have given a buy rating, and 1 has given a strong buy rating for NVS.

Consensus Price Target

$120.33
-7.47% Downside

According to the 10 analysts' twelve-month price targets for Novartis, the average price target is $120.33. The highest price target for NVS is $123.00, while the lowest price target for NVS is $118.00. The average price target represents a forecasted downside of -7.47% from the current price of $130.05.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for NVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novartis and its competitors.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVS Analyst Ratings Over Time

Type	Current Forecast 10/11/24 to 10/11/25	1 Month Ago 9/11/24 to 9/11/25	3 Months Ago 7/13/24 to 7/13/25	1 Year Ago 10/12/23 to 10/11/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	0 Buy rating(s)
Hold	4 Hold rating(s)	5 Hold rating(s)	6 Hold rating(s)	7 Hold rating(s)
Sell	3 Sell rating(s)	2 Sell rating(s)	3 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$120.33	$124.33	$123.67	$120.70
Forecasted Upside	-7.47% Downside	-2.58% Downside	2.26% Upside	3.84% Upside
Consensus Rating	Hold	Hold	Hold	Reduce

NVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novartis Stock vs. The Competition

Type	Novartis	Medical Companies	S&P 500
Consensus Rating Score	2.10	2.33	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	-7.47% Downside	1,022.57% Upside	177.75% Upside
News Sentiment Rating	Positive News See Recent NVS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/8/2025	Weiss Ratings 0 of 5 stars		Reiterated Rating	Buy (B)
9/12/2025	The Goldman Sachs Group 3 of 5 stars	James Quigley Not Rated	Reiterated Rating	Neutral ➝ Sell	$119.00 ➝ $118.00	-7.54%
8/21/2025	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Reiterated Rating	Buy
8/8/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Underweight ➝ Equal Weight	$123.00	+6.14%
4/15/2025	BNP Paribas Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	P. Verdult Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
2/13/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Weston Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
2/3/2025	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Underweight
12/4/2024	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold ➝ Reduce
11/19/2024	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
10/30/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Market Perform	$118.00 ➝ $120.00	+8.53%
9/11/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$135.00 ➝ $130.00	+11.08%
9/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:22 AM ET.

Should I Buy Novartis Stock? NVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 7, 2025. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

Novartis
Bull Case

Here are some ways that investors could benefit from investing in Novartis AG:

The current stock price is around $128, reflecting a recent increase, which may indicate positive market sentiment towards the company.
Novartis AG reported a strong quarterly earnings performance, with earnings per share (EPS) of $2.42, surpassing analyst expectations, which suggests robust financial health.
The company has shown a year-over-year revenue growth of 12.3%, indicating effective business strategies and product demand.
Analysts have a consensus rating of "Hold" for Novartis AG, with a target price averaging around $120.33, suggesting potential for stable returns.
With a net margin of 25.64% and a return on equity of 41.08%, Novartis AG demonstrates strong profitability and efficient use of shareholder equity.

Novartis
Bear Case

Investors should be bearish about investing in Novartis AG for these reasons:

Goldman Sachs has reiterated a "sell" rating with a price target of $118, indicating a lack of confidence in the stock's short-term performance.
Despite recent growth, the stock has a relatively low beta of 0.63, suggesting it may not be as responsive to market movements, which could limit potential gains.
There are three analysts who have rated the stock as a "Sell," which may reflect concerns about future performance and market conditions.
The company's debt-to-equity ratio of 0.53, while manageable, indicates that it is not entirely free from leverage, which could pose risks in a rising interest rate environment.
With a price-to-earnings (P/E) ratio of 18.66, the stock may be considered overvalued compared to industry peers, which could deter value-focused investors.

NVS Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Novartis is $120.33, with a high forecast of $123.00 and a low forecast of $118.00.
: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 3 sell ratings, 4 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
: According to analysts, Novartis's stock has a predicted downside of -7.47% based on their 12-month stock forecasts.
: Over the previous 90 days, Novartis's stock had 1 upgrade by analysts.
: Novartis has been rated by research analysts at Deutsche Bank Aktiengesellschaft, Morgan Stanley, The Goldman Sachs Group, and Weiss Ratings in the past 90 days.
: Analysts like Novartis less than other "medical" companies. The consensus rating score for Novartis is 2.10 while the average consensus rating score for "medical" companies is 2.33. Learn more on how NVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:NVS) was last updated on 10/11/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novartis (NVS) Stock Forecast & Price Target